title: [Epidemiology and drug susceptibility of Pseudomonas aeruginosa strains isolated in the Chugoku region of Japan. Infection Forum in the Chugoku Region].
abstract: Recently, there have been reports concerning an increased frequency of isolation of multi-drug resistant Pseudomonas aeruginosa (MDRP) strains in hospitals and other clinical settings as well as the associated risk of their hospital-acquired infections; in such a situation, it has been a major challenge to establish methods of managing and treating the infections. In order to investigate the trend of P. aeruginosa, the Infection Forum in the Chugoku Region has conducted to a multi-center collaborative study to isolate P. aeruginosa strains from sputum and urine samples collected between October 2006 and September 2008, analyzed the drug susceptibility and the pulsed-field gel electrophoresis (PFGE) patterns of each strain, and assessed epidemiologic characteristics. Of the 738 P. aeruginosa strains collected in this study, 152 (20.6%), 179 (24.3%), 47 (6.4%), and 39 (5.3%) were found to be ciprofloxacin-resistant, imipenem-resistant, amikacin-resistant, and MDRP, respectively. Among the various antimicrobial agents tested, arbekacin (ABK) revealed the strongest inhibitory effects on each drug-resistant and MDRP strain; therefore, ABK was considered as a potential candidate for future treatment of diseases caused by P. aeruginosa. The study also showed that the detection rates of MDRP varied a lot from hospital to hospital. In addition, PFGE-based cluster analyses revealed several strains isolated in the same hospital exhibited a similar PFGE pattern and the same drug susceptibility, suggesting the presence of "unique" hospital-specific strains.
authors: Department of Internal Medicine, Hiroshima Prefecture Hospital.
authors: Masao
authors: M
authors: Kuwabara
authors: Nobuchika
authors: N
authors: Kusano
authors: Eiji
authors: E
authors: Shimizu
authors: Wataru
authors: W
authors: Shimizu
authors: Kanao
authors: K
authors: Kobayashi
authors: Shuntaro
authors: S
authors: Koda
authors: Masao
authors: M
authors: Doi
authors: Motoyuki
authors: M
authors: Sugai
authors: Hiromi
authors: H
authors: Kumon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D003428:Cross Infection / Q000453:epidemiology* / Q000382:microbiology*; D024881:Drug Resistance, Bacterial; D018432:Drug Resistance, Multiple; D016521:Electrophoresis, Gel, Pulsed-Field; D005260:Female; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000453:epidemiology* / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification*; D013183:Sputum / Q000382:microbiology; D014556:Urine / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D015378:Imipenem; D000583:Amikacin